Further studies reported the downregulation of DLC1 in other human cancers including lung, breast, renal, cutaneous melanomas, nasopharyngeal (NPC), esophageal, cervical, and prostate cancers [2–7]. This evidence concerns the gene DLC1 and Familial prostate cancer.